search
Back to results

Remote Ischemic Conditioning in Aneurysmal SAH (RESCUE-SAH)

Primary Purpose

Subarachnoid Hemorrhage, Aneurysmal, Delayed Cerebral Ischemia

Status
Recruiting
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Remote Ischemic Conditioning with Automatic Tourniquet Device
Sham Remote Ischemic Conditioning with Automatic Tourniquet Device
Sponsored by
Aarhus University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Subarachnoid Hemorrhage, Aneurysmal focused on measuring Remote Ischemic Conditioning, Subarachnoid Hemorrhage, Aneurysm, Delayed Cerebral Ischemia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Aneurysmal subarachnoid hemorrhage confirmed by computed tomography (CT) with aneurysm origin confirmed by computed tomography angiography (CTA) or digital subtraction angiography (DSA) Aneurysmal subarachnoid hemorrhage symptom-onset ≤ 3 days Aneurysm protected by clipping or coiling Independent in daily living before symptom onset (mRS ≤ 2) Exclusion Criteria: Subarachnoid hemorrhage caused by a lesion other than cerebral aneurysm Symptomatic vasospasm at the time of enrollment Previous cerebral lesion e.g. symptomatic cerebral infarction (>2cm), multiple sclerosis, symptomatic intracerebral hemorrhage, tumour, prior neurosurgery (excluding prior clipping or coiling of cold aneurysms without complications). History of severe peripheral vascular disease or signs of severe peripheral vascular disease on physical examination History of deep vein thrombosis or signs of deep vein thrombosis on physical examination Kidney involvement or prior kidney disease with an estimated glomerular filtration rate (eGFR) below safe levels for contrast infusion in relation to CT-perfusion. Pregnancy (Women of child-bearing age will have serum-Humane Choriogonadotropine taken prior to final inclusion. If pregnancy cannot be ruled out,the patient can't be included. Women with a safe birth control method will be encouraged to use this method during the entire period of active treatment.) Concomitant other acute life-threatening medical or surgical condition

Sites / Locations

  • Department of Neurosurgery, Aarhus University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Remote Ischemic Conditioning

Sham-RIC

Arm Description

After randomization a large thigh blood pressure cuff will be placed on the lower limb. The cuff will be inflated to a pressure 30 mm Hg greater than the systolic arterial blood pressure measured by the patient's arterial line or upper limb blood pressure cuff. The adequate level of inflation will be confirmed by the absence of pulse in the ipsilateral pedal artery detected by palpation. If the pulse signal is still present, the cuff will be inflated further until it disappears. The cuff will remain inflated for 5 minutes. Then the cuff will be deflated and the limb allowed to re-perfuse for 5 minutes. The procedure will be repeated five times followed by reperfusion. The first session will be performed 24-72 hours after the initial hemorrhage, within the first 24 hours after treatment of aneurysm, and repeated every 24 hours, between 8-10 am, until post hemorrhagic day 14.

After randomization a large leg blood pressure cuff will be placed on the lower limb. This cuff is not attached to the device, but appears to be. The device will the be operated by trained staff. A hidden cuff is attached to the device to ensure that the device produces regular operation noises. The hidden cuff (not attached to patient) is inflated. The cuff will remain inflated for 5 minutes, then the cuff will be deflated for 5 minutes. The procedure will be repeated for five cycles. The first session will be performed 48-72 hours after the initial hemorrhage, at least 24 hours after treatment of aneurysm and repeated every 24 hours, between 8-10 am, until post hemorrhagic day 14.

Outcomes

Primary Outcome Measures

Clinical outcome after 6 months measured by modified Rankin scale score (0-6, Higher score indicates worse outcome)
Assessed by telephone interview. Patient assessor is blinded to intervention

Secondary Outcome Measures

Difference in Infarct growth
Assessed by MRI, measured by segmentation and calculation of infarct volume.
Clinical outcome after 14 days measured by modified Rankin scale score (0-6, Higher score indicates worse outcome)
Assessed by clinician in charge of patient discharge.
Occurrence of delayed cerebral ischemia
Neurological deterioration after aSAH where DCI is deemed most likely cause, supported by angiography/perfusion CT.
Mortality after 3 months
Assessed via patient records. Assessor is blinded to intervention.
Mortality after 12 months
Assessed via patient records. Assessor is blinded to the intervention.
Presence of angiographic vasospasm on CT angiography baseline vs 8-day scan
Evaluated by a neuro-radiologist with more than 10 years of experience in intracerebral angiography. Assessor is blinded to intervention.

Full Information

First Posted
September 5, 2023
Last Updated
September 28, 2023
Sponsor
Aarhus University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT06032533
Brief Title
Remote Ischemic Conditioning in Aneurysmal SAH
Acronym
RESCUE-SAH
Official Title
The Effect of Remote Ischemic Conditioning on Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage: A Prospective, Randomized, Patient-assessor Blinded, Sham-controlled Pilot Study Investigating Effect on Clinical Outcome.
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 9, 2023 (Actual)
Primary Completion Date
November 30, 2027 (Anticipated)
Study Completion Date
November 30, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Aarhus University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this clinical trial is to examine the effect of limb occlusion therapy (remote ischemic conditioning, RIC) in subjects with aneurysmal subarachnoid hemorrhage. The main question it aims to answer is whether RIC can improve long-term recovery in participants with aneurysmal subarachnoid hemorrhage. Researchers will compare levels of functional independence in participants in the RIC-group to participants in the sham-group.
Detailed Description
Aneurysmal subarachnoid hemorrhage (aSAH) is one of the most devastating types of stroke. Half of the patients die during the acute ictus, and those who survive have a poor prognosis as 20-30% are disabled or eventually die from the disease. In the acute phase after aSAH, the most devastating complication is rebleeding, whereas in the late phase, delayed cerebral ischemia (DCI) is another feared complication, associated with high morbidity and mortality. Symptoms of DCI occur in 30 % of patients and 15-20 % of patients will develop a disabling stroke due to DCI. DCI typically occurs between days 4 and 14 after the initial bleeding. The cause of DCI is not fully understood. Cerebral vasospasms (CVS) are commonly seen on angiography in the first 4-14 days after initial bleeding, and have been linked to late onset of symptoms of focal ischaemia since the 60s. Modern research suggests that the pathophysiology is multifactorial, but CVS is still thought to be a major contributor. Other contributing factors are thought to be microthrombosis, microvascular spasm, oxidative stress, cortically spreading depolarizations, cell death, breakdown of blood-brain barrier, among others. Treatment with nimodipine is standard-of-care and is the only pharmacological intervention that has been shown to improve outcome in aSAH patients, although it has no impact on large-vessel CVS[. The need for developing effective methods for prevention or treatment of DCI persists, and an effective prophylactic treatment may have a large impact on the general outcome of aSAH. Ischemic conditioning is a potent activator of endogenous protection against ischemic injury. RIC can be applied as repeated short-lasting ischemia in a distant tissue that results in protection against subsequent long-lasting ischemic injury in the target organ. This protection can be applied prior to or during a prolonged ischemic event as remote ischemic preconditioning (RIPreC) and perconditioning (RIPerC), respectively. RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-minute cycles of limb ischemia alternating with 5 minutes of reperfusion. RIC activates several protective mechanisms, through humoral and neural pathways and shows promise in the setting of acute stroke. Inflammation initiated by cerebral ischemia can contribute to secondary brain injury and is correlated with poor outcome. Following ischemia there is a harmful excess leukocyte infiltration in the brain parenchyma, and in experimental studies on aSAH, pharmacological inhibition of cytokines has been associated with improved outcome. RIC has been demonstrated to reduce inflammation and downregulate inflammatory markers. In addition, RIC has protective effects on cerebral endothelial function and induces vasodilation, increasing cerebral blood flow (CBF). Angiogenesis, erythropoietin and nitric oxide (NO) are suggested to induce neuroprotection and stimulation of these strategies by conditioning including inhibition of inflammation has the potential to play an important part in treatment of patients after aSAH. The effect of RIC on blood and cerebrospinal fluid biomarkers has never been explored in the setting of aSAH. To-date, no serious adverse events have been documented in RIC. The procedure has been applied in numerous cardiovascular ischemic patients and in patients suffering from ischemic stroke and cerebral hemorrhage (ICH/SAH). A recent smaller randomized trials of RIPreC after aSAH showed promising results with regards to functional outcomes and incidence of cerebral oxygen desaturation, likewise without adverse effects of RIC. RIC is a non-pharmacologic and non-invasive treatment without noticeable discomfort that has neuroprotective potential worldwide. Aneurysmal SAH and subsequent DCI represents a unique clinical opportunity to test RIC as DCI typically manifests within the first 14 days after ictus and is often a significant contributor to neurological injury. The treatment is feasible, safe, and rooted in well-explored physiological concepts. There is a clear scientific gap and opportunity to explore RIC in the setting of aSAH and DCI in larger randomized trials.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Subarachnoid Hemorrhage, Aneurysmal, Delayed Cerebral Ischemia
Keywords
Remote Ischemic Conditioning, Subarachnoid Hemorrhage, Aneurysm, Delayed Cerebral Ischemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants are randomized to either daily treatment with remote ischemic conditioning or daily sham-treatment.
Masking
ParticipantOutcomes Assessor
Masking Description
Outcomes assessors are recruited from another department, and have not been involved with subjects prior to the telephone interview. Participants and outcome assessors are blinded to subject intervention.
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Remote Ischemic Conditioning
Arm Type
Experimental
Arm Description
After randomization a large thigh blood pressure cuff will be placed on the lower limb. The cuff will be inflated to a pressure 30 mm Hg greater than the systolic arterial blood pressure measured by the patient's arterial line or upper limb blood pressure cuff. The adequate level of inflation will be confirmed by the absence of pulse in the ipsilateral pedal artery detected by palpation. If the pulse signal is still present, the cuff will be inflated further until it disappears. The cuff will remain inflated for 5 minutes. Then the cuff will be deflated and the limb allowed to re-perfuse for 5 minutes. The procedure will be repeated five times followed by reperfusion. The first session will be performed 24-72 hours after the initial hemorrhage, within the first 24 hours after treatment of aneurysm, and repeated every 24 hours, between 8-10 am, until post hemorrhagic day 14.
Arm Title
Sham-RIC
Arm Type
Sham Comparator
Arm Description
After randomization a large leg blood pressure cuff will be placed on the lower limb. This cuff is not attached to the device, but appears to be. The device will the be operated by trained staff. A hidden cuff is attached to the device to ensure that the device produces regular operation noises. The hidden cuff (not attached to patient) is inflated. The cuff will remain inflated for 5 minutes, then the cuff will be deflated for 5 minutes. The procedure will be repeated for five cycles. The first session will be performed 48-72 hours after the initial hemorrhage, at least 24 hours after treatment of aneurysm and repeated every 24 hours, between 8-10 am, until post hemorrhagic day 14.
Intervention Type
Device
Intervention Name(s)
Remote Ischemic Conditioning with Automatic Tourniquet Device
Intervention Description
5 Cycles of Remote Ischemic Conditioning performed on the leg. One cycle consists of 5 minutes of arterial occlusion followed by 5 minutes of reperfusion. The above is repeated daily for 14 days or until patient is discharged. Patients are randomized to either active Remote Ischemic Conditioning or Sham-treatment.
Intervention Type
Device
Intervention Name(s)
Sham Remote Ischemic Conditioning with Automatic Tourniquet Device
Other Intervention Name(s)
Sham
Intervention Description
5 Cycles of sham-treatment performed on the leg. One cycle consists of 5 minutes of sham-treatment followed by 5 minutes of pause. The above is repeated daily for 14 days or until patient is discharged. Patients are randomized to either active Remote Ischemic Conditioning or Sham-treatment.
Primary Outcome Measure Information:
Title
Clinical outcome after 6 months measured by modified Rankin scale score (0-6, Higher score indicates worse outcome)
Description
Assessed by telephone interview. Patient assessor is blinded to intervention
Time Frame
Assessed 6 months after initial aneurysm rupture.
Secondary Outcome Measure Information:
Title
Difference in Infarct growth
Description
Assessed by MRI, measured by segmentation and calculation of infarct volume.
Time Frame
MRI performed 4-6 weeks after initial hemorrhage.
Title
Clinical outcome after 14 days measured by modified Rankin scale score (0-6, Higher score indicates worse outcome)
Description
Assessed by clinician in charge of patient discharge.
Time Frame
14 days after initial hemorrhage.
Title
Occurrence of delayed cerebral ischemia
Description
Neurological deterioration after aSAH where DCI is deemed most likely cause, supported by angiography/perfusion CT.
Time Frame
Within first 14 days after initial hemorrhage.
Title
Mortality after 3 months
Description
Assessed via patient records. Assessor is blinded to intervention.
Time Frame
Assessed at 3 months post initial hemorrhage
Title
Mortality after 12 months
Description
Assessed via patient records. Assessor is blinded to the intervention.
Time Frame
Assessed at 12 months post initial hemorrhage
Title
Presence of angiographic vasospasm on CT angiography baseline vs 8-day scan
Description
Evaluated by a neuro-radiologist with more than 10 years of experience in intracerebral angiography. Assessor is blinded to intervention.
Time Frame
8-9 days post initial hemorrhage.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aneurysmal subarachnoid hemorrhage confirmed by computed tomography (CT) with aneurysm origin confirmed by computed tomography angiography (CTA) or digital subtraction angiography (DSA) Aneurysmal subarachnoid hemorrhage symptom-onset ≤ 3 days Aneurysm protected by clipping or coiling Independent in daily living before symptom onset (mRS ≤ 2) Exclusion Criteria: Subarachnoid hemorrhage caused by a lesion other than cerebral aneurysm Symptomatic vasospasm at the time of enrollment Previous cerebral lesion e.g. symptomatic cerebral infarction (>2cm), multiple sclerosis, symptomatic intracerebral hemorrhage, tumour, prior neurosurgery (excluding prior clipping or coiling of cold aneurysms without complications). History of severe peripheral vascular disease or signs of severe peripheral vascular disease on physical examination History of deep vein thrombosis or signs of deep vein thrombosis on physical examination Kidney involvement or prior kidney disease with an estimated glomerular filtration rate (eGFR) below safe levels for contrast infusion in relation to CT-perfusion. Pregnancy (Women of child-bearing age will have serum-Humane Choriogonadotropine taken prior to final inclusion. If pregnancy cannot be ruled out,the patient can't be included. Women with a safe birth control method will be encouraged to use this method during the entire period of active treatment.) Concomitant other acute life-threatening medical or surgical condition
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kim M Ørskov, MD
Phone
+4542791933
Email
kimoer@rm.dk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Grethe Andersen, Prof., MD
Organizational Affiliation
Department of Neurology, Aarhus University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Arzu Bilgin-Freiert, MD, PhD
Organizational Affiliation
Department of Neurosurgery
Official's Role
Study Director
Facility Information:
Facility Name
Department of Neurosurgery, Aarhus University Hospital
City
Aarhus N
State/Province
Danmark
ZIP/Postal Code
DK-8200
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jens Christian H Sørensen, Prof., MD
First Name & Middle Initial & Last Name & Degree
Arzu Bilgin-Freiert, MD, PhD
Phone
+4529474197
Email
arzbil@rm.dk
First Name & Middle Initial & Last Name & Degree
Kim M Ørskov, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Individual participant data that underlie the results reported in this article after de-identification of participants
IPD Sharing Time Frame
Beginning 3 moths and ending 5 years following publication of results
IPD Sharing Access Criteria
Proposals should be directed to kimoer@rm.dk. To gain access data requestors will need to sign a data processing agreement.
Citations:
PubMed Identifier
26585977
Citation
Hess DC, Blauenfeldt RA, Andersen G, Hougaard KD, Hoda MN, Ding Y, Ji X. Remote ischaemic conditioning-a new paradigm of self-protection in the brain. Nat Rev Neurol. 2015 Dec;11(12):698-710. doi: 10.1038/nrneurol.2015.223. Epub 2015 Nov 20.
Results Reference
background
PubMed Identifier
25072112
Citation
Gonzalez NR, Connolly M, Dusick JR, Bhakta H, Vespa P. Phase I clinical trial for the feasibility and safety of remote ischemic conditioning for aneurysmal subarachnoid hemorrhage. Neurosurgery. 2014 Nov;75(5):590-8; discussion 598. doi: 10.1227/NEU.0000000000000514.
Results Reference
background
Links:
URL
https://www.uptodate.com/contents/aneurysmal-subarachnoid-hemorrhage-treatment-and-prognosis
Description
Background on Aneurysmal Subarachnoid Hemorrhage and Delayed Cerebral Ischemia

Learn more about this trial

Remote Ischemic Conditioning in Aneurysmal SAH

We'll reach out to this number within 24 hrs